Lantheus Holdings Inc. Common Stock (LNTH)

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pu…

Sector

Health Care

Industry

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Employees

1,193

Website

www.lantheus.com

Fundamentals

1-day range

$100.85$101.1

Market cap

$6.59B

P/E (trailing)

24.15

P/E (forward)

15.96

EPS (trailing)

$4.18

Dividend yield

—

Beta

-0.03

Avg. volume

1.31M

Forecasts

9 analyst ratings

Lantheus Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• LNTH

  Lantheus Holdings Inc. Common Stock

  $100.77

  ▲ 0.30%
  Market cap $6.59BP/E 24.15
  $49.67$111.86
• ORKA

  Oruka Therapeutics Inc. Common Stock

  $91.07

  ▼ 5.67%
  Market cap $5.72BP/E —
  $14.61$115.52
• NEOG

  Neogen Corporation Common Stock

  $11.67

  ▼ 0.60%
  Market cap $2.59BP/E —
  $4.9$12.85
• NNNN

  Anbio Biotechnology Class A Ordinary Shares

  $7.64

  ▼ 1.80%
  Market cap $1.53BP/E 144.72
  $6.61$51.33
• NTLA

  Intellia Therapeutics Inc. Common Stock

  $12.87

  ▼ 1.83%
  Market cap $1.50BP/E —
  $7.95$28.25
• ACHV

  Achieve Life Sciences Inc. Common Shares

  $8.09

  ▼ 1.16%
  Market cap $648.81MP/E —
  $2.62$8.61
• TKNO

  Alpha Teknova Inc. Common Stock

  $7.13

  ▼ 2.46%
  Market cap $284.15MP/E —
  $1.91$7.84

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Healthcare Equipment and Supplies Stocks Q2 Recap: Benchmarking Lantheus (NASDAQ:LNTH)
  Yahoo · 8/20/2026
• Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
  Yahoo · 8/14/2026
• FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
  Benzinga · 8/14/2026
• Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
  Benzinga · 8/14/2026
• Lantheus Holdings: Why I Am Exiting Before The Merger Closes
  SeekingAlpha · 8/10/2026
• Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026
  Yahoo · 8/6/2026
• Lantheus Reports Second Quarter 2026 Financial Results
  Yahoo · 8/6/2026
• Lantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate
  Benzinga · 8/6/2026

• Gerard Ber · May 14, 2026 · Tax Withholding

  381 @ $96.67
• Mary Anne Heino · May 14, 2026 · Tax Withholding

  1.2K @ $96.67
• Phuong Khanh Morrow · May 14, 2026 · Grant

  4.1K
• Heinz Christoph Maeusli · May 14, 2026 · Grant

  4.1K
• Gary J. Pruden · May 14, 2026 · Grant

  4.1K
• Minnie Baylor-Henry · May 14, 2026 · Grant

  4.1K
• Gerard Ber · May 14, 2026 · Grant

  4.1K
• Julia Marie Eastland · May 14, 2026 · Grant

  4.1K
• Julie McHugh · May 14, 2026 · Grant

  4.1K
• James H. Thrall · May 14, 2026 · Grant

  4.1K
• Sam R. Leno · May 14, 2026 · Grant

  4.1K
• Daniel Niedzwiecki · April 17, 2026 · Tax Withholding

  1.9K @ $83.82
• Daniel Niedzwiecki · March 5, 2026 · Tax Withholding

  1.3K @ $76.31
• Daniel Niedzwiecki · March 5, 2026 · Grant

  36.7K
• Ludger Dinkelborg · March 5, 2026 · Grant

  21.0K

Institutional Ownership

March 31, 2026

Total shares held

67.20M

Total value held

$4.97B

Institutional holders

395